Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer

Golan, Talia; Hammel, Pascal; Reni, Michele; Van Cutsem, Eric; Macarulla, Teresa; J. Hall, Michael; Park, Joon-Oh; Hochhauser, Daniel; Arnold, Dirk; Oh, Do‐Youn; Reinacher‐Schick, Anke; Tortora, Giampaolo; Algül, Hana; M. O’Reilly, Eileen; McGuinness, David; Cui, Karen; Schlienger, Katia; Y. Locker, Gershon; L. Kindler, Hedy

doi:10.1056/nejmoa1903387

Public

Maintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic Cancer

Published in New England Journal of Medicine • Jun 2, 2019

Authors:

Talia Golan

Pascal Hammel

Michele Reni

Abstract

BACKGROUND: mutation make up a small subgroup of those with metastatic pancreatic cancer. The poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitor olaparib has had antitumor activity in this population. METHODS: mutation and metastatic pancreatic cancer and disease that had not progressed ...

Subject

Olaparib

Germline

PARP inhibitor

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!